Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ORPH NASDAQ:TFFP NASDAQ:VTGN NASDAQ:VYNE NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23$289K0.98983,915 shsN/AVTGNVistaGen Therapeutics$2.38-2.1%$2.29$1.90▼$4.01$70.85M0.61186,981 shs195,617 shsVYNEVYNE Therapeutics$1.42+2.9%$1.17$0.85▼$4.30$20.99M1.78223,060 shs670,275 shsWVEWAVE Life Sciences$7.70-3.1%$6.71$5.04▼$16.74$1.24B-1.011.30 million shs1.39 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-96.78%VTGNVistaGen Therapeutics-2.06%+17.53%+0.85%+12.26%-31.61%VYNEVYNE Therapeutics+2.90%+2.90%+54.05%-8.68%-26.42%WVEWAVE Life Sciences-3.14%+10.47%+7.09%+36.28%+38.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVTGNVistaGen Therapeutics0.9288 of 5 stars0.01.00.00.03.31.71.3VYNEVYNE Therapeutics2.8065 of 5 stars3.53.00.00.02.71.70.6WVEWAVE Life Sciences4.5482 of 5 stars3.52.00.04.82.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceORPHOrphazyme A/S 0.00N/AN/AN/ATFFPTFF Pharmaceuticals 0.00N/AN/AN/AVTGNVistaGen Therapeutics 3.00BuyN/AN/AVYNEVYNE Therapeutics 3.00Buy$6.25340.14% UpsideWVEWAVE Life Sciences 2.92Moderate Buy$20.50166.23% UpsideCurrent Analyst Ratings BreakdownLatest TFFP, WVE, ORPH, VYNE, and VTGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025WVEWAVE Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.006/18/2025VTGNVistaGen TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform6/11/2025WVEWAVE Life SciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.004/29/2025WVEWAVE Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/25/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.75 ➝ $4.50(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/ATFFPTFF Pharmaceuticals$730K0.40N/AN/A$4.04 per share0.02VTGNVistaGen Therapeutics$490K141.63N/AN/A$2.44 per share0.98VYNEVYNE Therapeutics$500K43.20N/AN/A$3.53 per share0.40WVEWAVE Life Sciences$108.30M11.06N/AN/A$1.37 per share5.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ATFFPTFF Pharmaceuticals-$21.24M-$6.44N/A∞N/AN/AN/AN/AN/AVTGNVistaGen Therapeutics-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)VYNEVYNE Therapeutics-$39.83M-$0.99N/AN/AN/A-6,974.55%-71.89%-58.94%8/13/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%8/14/2025 (Estimated)Latest TFFP, WVE, ORPH, VYNE, and VTGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025VTGNVistaGen Therapeutics-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million5/8/2025Q1 2025WVEWAVE Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthORPHOrphazyme A/SN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioORPHOrphazyme A/S0.141.80N/ATFFPTFF PharmaceuticalsN/AN/AN/AVTGNVistaGen TherapeuticsN/A6.516.51VYNEVYNE TherapeuticsN/A4.474.47WVEWAVE Life SciencesN/A2.952.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipORPHOrphazyme A/S10.74%TFFPTFF Pharmaceuticals15.25%VTGNVistaGen Therapeutics78.39%VYNEVYNE Therapeutics83.78%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipORPHOrphazyme A/SN/ATFFPTFF Pharmaceuticals4.50%VTGNVistaGen Therapeutics1.29%VYNEVYNE Therapeutics4.80%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionableVTGNVistaGen Therapeutics4029.16 million28.78 millionOptionableVYNEVYNE Therapeutics3015.21 million14.48 millionNot OptionableWVEWAVE Life Sciences240155.56 million118.26 millionOptionableTFFP, WVE, ORPH, VYNE, and VTGN HeadlinesRecent News About These CompaniesLeerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24July 11 at 2:20 PM | msn.comNASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.comJuly 11 at 4:17 AM | investing.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 6.8% - Should You Buy?July 9 at 6:03 PM | marketbeat.comBrokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) PT at $20.50July 9 at 2:43 AM | americanbankingnews.comWAVE Life Sciences Ltd. Company & People | WVE | Barron'sJuly 7, 2025 | barrons.comWave Life Sciences: Upgrading Rating To Buy After Turbulent 10 MonthsJuly 7, 2025 | seekingalpha.comWave Life Sciences: Speculative, But PromisingJuly 7, 2025 | seekingalpha.comWave Life Sciences Ltd. (WVE) - Yahoo FinanceJuly 6, 2025 | finance.yahoo.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 6, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 6, 2025 | marketbeat.comMoody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)July 4, 2025 | marketbeat.comH.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data ReleaseJuly 3, 2025 | msn.comWhere WAVE Life Sciences Stands With AnalystsJune 23, 2025 | benzinga.comWAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from WedbushJune 23, 2025 | marketbeat.comWave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...June 22, 2025 | manilatimes.netMWave Life Sciences Presents Promising Preclinical Data for WVE-007, a Novel siRNA Obesity Treatment at American Diabetes Association MeetingJune 22, 2025 | nasdaq.comWave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ...June 20, 2025 | finance.yahoo.comWave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific SessionsJune 20, 2025 | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?June 20, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Time to Sell?June 19, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Director Sells $208,500.00 in StockJune 14, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTFFP, WVE, ORPH, VYNE, and VTGN Company DescriptionsOrphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.TFF Pharmaceuticals NASDAQ:TFFP$0.06 0.00 (0.00%) As of 04/10/2025TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.VistaGen Therapeutics NASDAQ:VTGN$2.38 -0.05 (-2.06%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.39 +0.01 (+0.42%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.VYNE Therapeutics NASDAQ:VYNE$1.42 +0.04 (+2.90%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.42 +0.01 (+0.35%) As of 07/11/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.WAVE Life Sciences NASDAQ:WVE$7.70 -0.25 (-3.14%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$7.80 +0.10 (+1.30%) As of 07/11/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
